Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
LATEST NEWS
SGLT-2 Inhibitor Reduces Risk of Cardiovascular Death: Should Current Guidelines be Impacted?
HOMERUN SLIDES — Great Clinical Presentation Highlights
The Present and Future of Insulin Therapy Part 18: Effects of Dapagliflozin
The Present and Future of Insulin Therapy Part Part 9: SGLT-2 Inhibition
Editor's Note
Last week I was watching football and it seems like there is a real advantage for teams who can switch easily between the running and passing games, proving that 2 offenses are better than one. The same appears to be true in diabetes care, and this month our SGLT-2 inhibitor newsletter focuses on using 2 offenses to treat diabetes, and how using insulin and an SGLT-2 inhibitor can make a great one-two punch for type 2 patients.
Your partner in diabetes care,
Dave Joffe
Editor-in-chief
LATEST NEWS
New study generates lively discussion among experts at EASD on how to consider the results in prescribing, exploration of possible mechanism and potential class effect.
HOMERUN SLIDES — Great Clinical Presentation Highlights
In this week’s Homerun Slides, the effect of dapagliflozin on endogenous glucose production, plasma insulin and glucagon concentration.
In this week’s Homerun Slides, we look at SGLT2 Inhibition as a novel treatment strategy for type 2 diabetes.